J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendershot, P.
Right arrow Articles by Hopkins, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendershot, P.
Right arrow Articles by Hopkins, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr

PE Hendershot, EJ Antal, IR Welshman, DH Batts, and NK Hopkins

Linezolid is a novel oxazolidinone antibiotic with mild reversible monoamine oxidase inhibitor (MAOI) activity. The potential for interaction with over-the-counter (OTC) medications requires quantification. The authors present data evaluating the pharmacokinetic and pharmacodynamic responses to coadministration of oral linezolid with sympathomimetics (pseudoephedrine and phenylpropanolamine) and a serotonin reuptake inhibitor (dextromethorphan). Following coadministration with linezolid, minimal but statistically significant increases were observed in pseudoephedrine and phenylpropanolamine plasma concentrations; a minimal but statistically significant decrease was observed in dextrorphan (the primary metabolite of dextromethorphan) plasma concentrations. Increased blood pressure (BP) was observed following the coadministration of linezolid with either pseudoephedrine or phenylpropanolamine; no significant effects were observed with dextromethorphan. None of these coadministered drugs had a significant effect on linezolid pharmacokinetics. Minimal numbers of adverse events were reported. Potentiation of sympathomimetic activity by linezolid was judged not to be clinically significant, but patients sensitive to the effects of increased BP due to predisposing factors should be treated cautiously. No restrictions are indicated for the coadministration of dextromethorphan and linezolid.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Beer, K. W. Engelhardt, B. Pfausler, G. Broessner, R. Helbok, P. Lackner, C. Brenneis, S. T. Kaehler, A. Georgopoulos, and E. Schmutzhard
Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 379 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. M. Salerno, J. L. Jackson, and E. P. Berbano
Effect of Oral Pseudoephedrine on Blood Pressure and Heart Rate: A Meta-analysis
Arch Intern Med, August 8, 2005; 165(15): 1686 - 1694.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
T. Gordi, L. H. Tan, C. Hong, N. J. Hopkins, S. F. Francom, J. G. Slatter, and E. J. Antal
The Pharmacokinetics of Linezolid Are Not Affected by Concomitant Intake of the Antioxidant Vitamins C and E
J. Clin. Pharmacol., October 1, 2003; 43(10): 1161 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Rubinstein, R. Isturiz, H. C. Standiford, L. G. Smith, T. H. Oliphant, S. Cammarata, B. Hafkin, V. Le, and J. Remington
Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1824 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. M. Lovering, J. Zhang, G. C. Bannister, B. J. A. Lankester, J. H. M. Brown, G. Narendra, and A. P. MacGowan
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement
J. Antimicrob. Chemother., July 1, 2002; 50(1): 73 - 77.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology